SLU-PP-332 250mcg

Mitochondria are highly dynamic double‑membrane organelles whose inner membrane forms folded cristae structures, which are the sites of oxidative phosphorylation (OXPHOS) and ATP production. The stability of cristae junctions (CJs) directly determines the efficiency of energy metabolism. In recent years, the MICOS complex has been confirmed as the key structure that maintains cristae morphology and inner‑/outer‑membrane contact.

However, the upstream transcriptional regulatory network of MICOS genes, especially the nuclear receptor–mitochondrial genome axis that can be pharmacologically activated, has long been unclear. Estrogen‑related receptor β (ERRβ/ERβ) is highly expressed in mitochondria and can directly bind to the mitochondrial genome (mtDNA) to regulate respiratory and structural genes. Slu‑PP‑332 250 mcg, as a selective and potent ERR agonist, can stably activate ERβ at this dose and initiate a specific signaling cascade to coordinate the expression of MICOS family genes.

The Entry Pathway of Slu-PP-332 into Mitochondria
After entering cells, Slu-PP-332 250mcg rapidly crosses the outer and inner mitochondrial membranes relying on its lipophilic structure. It binds to the ligand‑binding domain (LBD) of ERβ in the mitochondrial matrix, induces conformational changes, promotes the dissociation of inhibitory proteins, and enhances the binding ability of ERβ to mtDNA. This process does not depend on the classical nuclear genomic pathway and can directly act on the mitochondrial genome, forming a fast, efficient, and mitochondria‑specific "secret dialogue."

Binding of ERβ to Mitochondrial Genome and Transcriptional Regulation
The mitochondrial genome contains conserved ERR/ER binding motifs (ERRE). After activation by Slu‑PP‑332 250 mcg, ERβ forms a homodimer or a heterodimer with PGC‑1α and directly binds to the D‑loop and coding regions of mtDNA. This binding promotes the recruitment of mitochondrial RNA polymerase (POLRMT) and transcription factors, upregulates the expression of mitochondrial‑encoded respiratory chain subunits, and simultaneously coordinates the transcription of nuclear‑encoded MICOS genes, realizing the mitonuclear balance of mitochondrial structure maintenance.

The Specificity of 250 mcg Dose in Mitochondrial Regulation
The 250 mcg dose is critical for mitochondrial targeting. Low doses fail to stably activate ERβ, while high doses may cause excessive receptor activation and non‑specific transcriptional interference. The 250 mcg dose can maintain moderate and sustained ERβ activity, maximize the upregulation of MICOS genes, and avoid mitochondrial structural damage caused by over‑activation. This dose has been verified in multiple cell and animal models to be the optimal effective dose for regulating MICOS and maintaining cristae stability.

Regulation of MIC60 (Mitofilin)
MIC60 is the core scaffold subunit of MICOS, responsible for maintaining cristae junctions and connecting the inner and outer membranes. Its promoter region contains multiple ERRE motifs. After activation by Slu‑PP‑332 250 mcg, ERβ directly binds to the MIC60 promoter and upregulates its transcription by 2–3‑fold. Increased MIC60 stabilizes cristae junctions, reduces mitochondrial fragmentation, and enhances the contact between the inner and outer membranes, promoting lipid transport and energy metabolism.

Regulation of MIC10 (MINOS1)
MIC10 is a key structural protein that bends the inner membrane and forms cristae. It contains a conserved GxGxGxG domain, which is critical for membrane curvature. Slu‑PP‑332 250 mcg significantly increases MIC10 expression through ERβ, promotes the oligomerization of MIC10, stabilizes cristae morphology, and improves the efficiency of oxidative phosphorylation. In NAFLD models, the upregulation of MIC10 effectively reduces hepatic lipid deposition.

Regulation of MIC19 (CHCHD3) and MIC25 (CHCHD6)
MIC19 and MIC25 are CHCH domain‑containing proteins that maintain the stability of the MICOS complex. MIC19 stabilizes MIC60, and MIC25 is involved in cristae extension and mitochondrial respiration. Slu‑PP‑332 250 mcg activates ERβ to coordinately upregulate MIC19 and MIC25, enhance the assembly of the MICOS complex, reduce the degradation of core subunits, and maintain the integrity of the mitochondrial inner membrane structure.

Regulation of MIC26 (APOO) and MIC27 (APOOL)
MIC26 and MIC27 are lipid‑binding subunits that connect MICOS with cardiolipin and participate in lipid metabolism and mitochondrial dynamics. Slu‑PP‑332 250 mcg upregulates MIC26/27 expression via ERβ, enhances cardiolipin binding, stabilizes the MICOS complex, promotes fatty acid oxidation, and reduces triglyceride accumulation. This regulatory effect is crucial for improving metabolic disorders such as obesity and NAFLD.

Maintaining Cristae Structure and Enhancing Respiratory Efficiency
By upregulating MICOS components, Slu‑PP‑332 250 mcg stabilizes cristae junctions, increases cristae density, and promotes the assembly of respiratory chain supercomplexes. This significantly improves mitochondrial oxygen consumption rate (OCR) and ATP production efficiency, enhances cellular oxidative metabolism, and reduces glycolysis dependence.

Promoting Fatty Acid Oxidation and Inhibiting Ectopic Lipid Deposition
The MICOS complex is closely related to mitochondrial lipid metabolism. Slu‑PP‑332 250 mcg improves the β‑oxidation efficiency of fatty acids by enhancing MICOS function, reduces the accumulation of free fatty acids and triglycerides in the liver and muscle, and improves insulin sensitivity. This is an important mechanism for its anti‑obesity and anti‑diabetic effects.

Resisting Metabolic Stress and Maintaining Mitochondrial Dynamics
Under metabolic stress (high fat, hyperglycemia, oxidative stress), MICOS is easily degraded, leading to mitochondrial damage. Slu‑PP‑332 250 mcg activates ERβ to maintain MICOS expression, inhibit mitochondrial fission, promote fusion, reduce reactive oxygen species (ROS) production, and protect cells from metabolic damage.

The therapeutic potential of metabolic diseases

Cardioprotective effect

In a mouse model of heart failure, ERR β activation significantly improved cardiac function, including an 18% increase in ejection fraction, a 25% increase in cardiac output, and a 40% reduction in myocardial fibrosis. The mechanism is closely related to the optimization of mitochondrial cristae structure by ERR β and the enhancement of respiratory chain complex activity. In addition, ERR β can also inhibit pathological myocardial remodeling, reduce myocardial cell apoptosis, and protect cardiac function.

The association between neurodegenerative diseases and tumors

Specific activation effect of low-dose Slu-PP-332

Research has shown that Slu-PP-332 can specifically activate ERR β at low doses (such as 250 mcg/kg), but has weaker activation effects on ERR α and ERR γ. This dose-dependent selective activation may be related to its distribution and metabolic characteristics in the body. Low dose Slu-PP-332 reaches target tissues (such as skeletal muscle and myocardium) through blood circulation, binds to ERR β, induces receptor conformational changes, promotes its binding to co activators (such as PGC-1 α), and activates downstream signaling pathways.